Thymosin-?_1 improving efficacy of Lamivudine treatment in patients with chronic hepatitis B / 中华传染病杂志
Chinese Journal of Infectious Diseases
;
(12)2001.
Artículo
en Chino
| WPRIM
| ID: wpr-553960
ABSTRACT
Objective To evaluate the long-term efficacy and safety profile of alpha-1-thymosin (T?_1) combined with Lamivudine(LAM) in the patients with chronic hepatitis B. Methods Eighty patients with chronic hepatitis B were randomly assigned by 1∶1 proportion to be given 100 mg LAM orally alone (LAM group) or T?_1 1.6 mg subcutaneous injection, combined with LAM(LAM+T?_1 group). Results 51.4 percent (18/35) of the patients achieved HBeAg seroconversion in combination group, while 5.4%(2/37) of the patients in LAM group achieved HBeAg seroconversion at 52 week, P
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Infectious Diseases
Año:
2001
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS